Boston Scientific (BSX) Stock Overview
Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BSX Community Fair Values
Create NarrativeSee what 65 others think this stock is worth. Follow their fair value or set your own to get alerts.
Acquisitions And Product Launches Will Expand US Medical Capacity
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$102.96 |
| 52 Week High | US$107.53 |
| 52 Week Low | US$71.88 |
| Beta | 0.68 |
| 1 Month Change | 2.92% |
| 3 Month Change | 11.14% |
| 1 Year Change | 33.52% |
| 3 Year Change | 180.01% |
| 5 Year Change | 180.55% |
| Change since IPO | 2,304.91% |
Recent News & Updates
Recent updates
Returns At Boston Scientific (NYSE:BSX) Are On The Way Up
Jul 04
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
May 30Boston Scientific's (NYSE:BSX) Solid Earnings Have Been Accounted For Conservatively
May 08Boston Scientific Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 25Estimating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Apr 23Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Apr 07Boston Scientific: Bright Future, Rather Pricey
Mar 18Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
Mar 05Boston Scientific (NYSE:BSX) Has More To Do To Multiply In Value Going Forward
Jan 29Is It Time To Consider Buying Boston Scientific Corporation (NYSE:BSX)?
Jan 15Boston Scientific Standing Apart As A Rare Med-Tech Growth Story
Jan 14Calculating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Jan 02Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?
Dec 19Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05
Axonics and FARAPULSE acquisitions to skyrocket market share and revenue in medical devices
Uncertainty surrounding the approval and U.S. launch timeline for ACURATE neo2 might affect projected revenues from the Structural Heart Valves franchise.Shareholder Returns
| BSX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.6% | -0.6% | 0.6% |
| 1Y | 33.5% | 9.9% | 12.4% |
Return vs Industry: BSX exceeded the US Medical Equipment industry which returned 10.7% over the past year.
Return vs Market: BSX exceeded the US Market which returned 12.6% over the past year.
Price Volatility
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 2.9% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: BSX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BSX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 53,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems.
Boston Scientific Corporation Fundamentals Summary
| BSX fundamental statistics | |
|---|---|
| Market cap | US$151.51b |
| Earnings (TTM) | US$2.03b |
| Revenue (TTM) | US$17.55b |
Is BSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSX income statement (TTM) | |
|---|---|
| Revenue | US$17.55b |
| Cost of Revenue | US$5.54b |
| Gross Profit | US$12.02b |
| Other Expenses | US$9.98b |
| Earnings | US$2.03b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 23, 2025
| Earnings per share (EPS) | 1.37 |
| Gross Margin | 68.45% |
| Net Profit Margin | 11.58% |
| Debt/Equity Ratio | 49.8% |
How did BSX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/09 03:58 |
| End of Day Share Price | 2025/07/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boston Scientific Corporation is covered by 69 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| Adam Feinstein | Barclays |